Insulin Resistance presentations about Insulin Resistance EB with interest for Insulin Resistance Validating Insulin Resistance content Free registration form / enregistrement gratuit
  Français - August 16, 2011
Welcome to the #1 online source of information for Diabetes Specialists! An international online community of more than 10,000 Diabetes Specialists.

CME on Diabetes is a website built to transmit top-level CME conferences given by international experts in endocrinology, insulin resistance, prediabetes, metabolic syndrome and type 2 diabetes. More than 2.6 million slides have been viewed since the website launch. Thank you for your continued support and commitment!

Diabetes and Cardiovascular Disease

Presentations listing

Cardiovascular disease trials with implications for... - Prof. Timothy Davis
The Indian diabetic diaspora: a cardiovascular time bomb - Dr. Soji Swaraj
The Cardiovascular Profile of Current Therapies: What is... - Dr. Trisha O'Moore-Sullivan
CVD in Type 2 Diabetes: Who and How to Investigate - Dr. Trisha O'Moore-Sullivan
Which Cardiovascular Disease Should We Screen for in... - Prof. Tom Marwick
Hypertension: Where We Have Been and Where We Are Going - Prof. George L. Bakris
Progress in Heart Failure: Outcomes Trials Resulting in... - Dr. James Young
Role of Noninvasive Imaging in the Approach to... - Prof. Valentin Fuster
Type 2 Diabetes and Cardiovascular Disease: The Neel... - Prof. Peter J. Grant
Diabetes Mellitus: A Prothrombotic State - Dr. Richard W. Nesto
Adiponectin - Novel 'Adipokine' with Metabolic and Vascular... - Dr. Barry Goldstein

"Cardiovascular disease trials with implications for diabetes: Getting the evidence in the modern era"

Prof. Timothy Davis (biography)
English - 2008-02-05 - 35 minutes
(42 slides)

Summary :
Professor Davis reviews several cardiovascular trials with implications for diabetes that have been conducted in recent years, with a focus on understanding the results. There are certain potential influences on clinical trials to keep in mind: the decrease in effect size due to the Hawthorn effect on the placebo group and due to more intensive management approaches, and the decrease in the...

Learning objectives :
After viewing this presentation the participant will be able to discuss:

The reasons for recent negative results in CVD trials with implications for diabetes, specifically -



"The Indian diabetic diaspora: a cardiovascular time bomb"

Dr. Soji Swaraj (biography)
English - 2007-11-16 - 21 minutes
(15 slides)

Summary :
In this presentation Dr. Swaraj discusses possible reasons for the high diabetes disease burden among people of East Indian origin, and prevention and treatment strategies.

Among countries, India has the highest number of people with diabetes. Among the Indian diaspora or Indians living outside of India, diabetes is more prevalent compared to their caucasian counterparts (1); they...

Learning objectives :
After viewing this presentation the participant will be able to discuss:

- Factors contributing to the high diabetes disease burden in people of East Indian origin
- Possible strategies to address this issue

Bibliographic references :
1. Raj Bhopal et al. Heterogeneity of coronary heart disease risk factors in Indian, Pakistani, Bangladeshi, and European origin populations: cross sectional study BMJ 1999;319:215-220.

2. C. J. K. Henry et al. Glycaemic index of common foods tested in the UK and India British Journal of Nutrition 2007.



"The Cardiovascular Profile of Current Therapies: What is the Verdict?"

Dr. Trisha O'Moore-Sullivan (biography)
English - 2007-11-10 - 30 minutes
(27 slides)

Summary :
In a recent systematic review published by Bolen et al., there was no strong evidence found for CVD benefit of any particular oral agent compared to another in type 2 diabetes treatment (1). There is however a lingering concern about sulfonylureas and cardiovascular risk. Some evidence raises concern about potential harm from sulfonylureas, though these data are largely from retrospective and...

Learning objectives :
After viewing this presentation the participant will be able to discuss:

- Results of a systematic review of the comparative effectiveness and safety of oral medications for type 2 diabetes (Bolen et al. Ann Int Med 2007)
- Data on sulfonylureas, metformin and insulin with respect to cardiovascular outcomes
- A systematic review of the literature on antidiabetic agents and morbidity and mortality in patients with diabetes and heart failure (Eurich et al., BMJ 2007)

Bibliographic references :
1. Shari Bolen et al. Systematic Review: Comparative Effectiveness and Safety of Oral Medications for Type 2 Diabetes Mellitus Ann Int Med 18 September 2007 | Volume 147 Issue 6 | Pages 386-399.

2. UK Prospective Diabetes Study (UKPDS) Group Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) The Lancet Volume 352, Issue 9131, 12 September 1998, Pages 854-865.

3. Dean T Eurich et al.Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review BMJ 2007;335:497.



"CVD in Type 2 Diabetes: Who and How to Investigate"

Dr. Trisha O'Moore-Sullivan (biography)
English - 2007-03-03 - 38 minutes
(40 slides)

Summary :
In this presentation Dr. O'Moore-Sullivan talks about investigations that can be done in type 2 diabetic patients who are symptomatic for coronary artery disease (CAD), and some potential means of identifying high-risk asymptomatic patients.

Coronary angiography is the "gold standard" for the detection of coronary artery disease (CAD), whereas multi-slice computed tomography,...

Learning objectives :
After viewing this presentation the participant will be able to discuss:

- Anatomical and functional tests for assessing CAD
- Imaging and prognosis in diabetic patients
- Data from the DIAD study: proportion of asymptomatic type 2 diabetic patients having an abnormal SPECT test
- The role of coronary artery calcium scoring in the identification of high-risk asymptomatic type 2 diabetic patients

Bibliographic references :
1. Bax JJ, Inzucchi SE, Bonow RO, Schuijf JD, Freeman MR, Barrett EJ; Global Dialogue Group for the Evaluation of Cardiovascular Risk in Patients with Diabetes.Cardiac Imaging for Risk Stratification in Diabetes Diabetes Care 30:1295-1304, 2007.

2. Wackers FJ, Young LH, Inzucchi SE, Chyun DA, Davey JA, Barrett EJ, Taillefer R, Wittlin SD, Heller GV, Filipchuk N, Engel S, Ratner RE, Iskandrian AE; Detection of Ischemia in Asymptomatic Diabetics Investigators.Detection of silent myocardial ischemia in asymptomatic diabetic subjects: the DIAD study. Diabetes Care 27:1954-1961, 2004.

3. Anand DV, Lim E, Hopkins D, Corder R, Shaw LJ, Sharp P, Lipkin D, Lahiri A. Risk stratification in uncomplicated type 2 diabetes: prospective evaluation of the combined use of coronary artery calcium imaging and selective myocardial perfusion scintigraphy Eur Heart J. 2006 Mar;27(6):713-21.



"Which Cardiovascular Disease Should We Screen for in Diabetes?"

Prof. Tom Marwick (biography)
English - 2007-03-03 - 37 minutes
(56 slides)

Summary :
Diabetic patients are at increased risk for heart failure, as seen in the Framingham Heart Study (1), and conversely there is an over-representation of diabetes in heart failure patients (2). The emphasis is now moving to treating the earlier stages A and B of heart failure, says Prof. Marwick. These are cases where risk factors for heart failure present, or risk factors plus some abnormal...

Learning objectives :
After viewing this presentation the participant will be able to discuss:

- Heart failure in diabetes: epidemiology, prognosis
- Features of preclinical diabetic heart disease
- The impact of preclinical diabetic heart disease on exercise capacity in T2DM
- Five potential mechanisms of diabetic heart disease

Bibliographic references :
1. Kannel WB, Hjortland M, Castelli WP. "Role of diabetes in congestive heart failure: the Framingham study." Am J Cardiol. 1974 Jul;34(1):29-34.

2. Coughlin SS, Pearle DL, Baughman KL, Wasserman A, Tefft MC.Diabetes mellitus and risk of idiopathic dilated cardiomyopathy. The Washington, DC Dilated Cardiomyopathy Study. Ann Epidemiol. 1994 Jan;4(1):67-74.

3. John K. Boyer MD, Srihari Thanigaraj MD, Kenneth B. Schechtman PhD and Julio E. Pérez MD.Prevalence of ventricular diastolic dysfunction in asymptomatic, normotensive patients with diabetes mellitus The American Journal of Cardiology Volume 93, Issue 7, 1 April 2004, Pages 870-875.



"Hypertension: Where We Have Been and Where We Are Going"

Prof. George L. Bakris (biography)
English - 2006-11-11 - 33 minutes
(21 slides)

Summary :
With the growing epidemic of obesity and the associated increase in the prevalence of diabetes and kidney disease comes an accompanying increase in the incidence of hypertension. Thus, the future portends more cardiovascular events associated with these conditions. This presentation is an overview of where we have been and where we are going with respect to control of hypertension.

Learning objectives :
After viewing this presentation the participant will be able to discuss:

- Trends in the prevalence of hypertension
- Hypertension awareness, treatment and control
- JNC and HWG blood pressure classifications
- Prevalence of prehypertension
- Cardiovascular disease risk factors/markers
- Findings from the TROPHY trial

Bibliographic references :
Beeks, Esther; Kessels, Alfons GH; Kroon, Abraham A; van der Klauw, Melanie M; de Leeuw, Peter W Genetic predisposition to salt-sensitivity: a systematic review. Journal of Hypertension. 22(7):1243-1249, July 2004.

Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW,Materson BJ, Oparil S, Wright JT Jr, Roccella EJ; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education
Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003 May 21;289(19):2560-72.

European Society of Hypertension-European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension [published corrections appear in J Hypertens. 2003;21:2203-2204 and J Hypertens.2004;22:435]. J Hypertens. 2003;21:1011-1053.

Kshirsagar AV, Carpenter M, Bang H, Wyatt SB, Colindres RE. Blood Pressure Usually Considered Normal Is Associated with an Elevated Risk of Cardiovascular Disease Am J Med. 2006 Feb;119(2):133-41.

Lewington S, Clarke R, Qizilbash N, Peto R, Collins R; Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies Lancet. 2002 Dec 14;360(9349):1903-13.



"Progress in Heart Failure: Outcomes Trials Resulting in Evidence-Based Interventions"

Dr. James Young (biography)
English - 2006-11-11 - 35 minutes
(35 slides)

Summary :
Progress in our understanding of heart failure can be defined by increasing insight into the enormous morbidity and mortality associated with this syndrome, as well as elucidation of its pathophysiology. Arguably, the “modern” day of heart failure awareness and therapy began in the mid-1960s when the syndrome was characterized more as a systemic cardiovascular disease than simply a problem...

Learning objectives :
After viewing this presentation the participant will be able to discuss:

- The facets of heart failure
- Historical perspectives on heart failure
- The emergence of clinical trials in heart failure
- Modern evolution of heart failure therapies



"Role of Noninvasive Imaging in the Approach to Atherosclerotic Disease in Diabetes"

Prof. Valentin Fuster (biography)
English - 2006-11-11 - 32 minutes
(58 slides)

Summary :
What are some strategic priorities concerning diabetes, atherothrombosis and imaging? In this presentation Prof. Fuster talks about the role of non-invasive imaging in the approach to atherosclerotic disease in diabetes.

Cardiovascular medicine is likely to focus more in the future on understanding and protecting health, and priorities may involve enhancing biological defense...

Learning objectives :
After viewing this presentation the participant will be able to discuss:

Atherothrombosis, Diabetes and Imaging: Predicting 8 strategic priorities for 2006-2015:
- From treatment to protecting health
- Three molecular/cell processes to enhance
- Four clinical risk groups to identify and protect

Bibliographic references :
1. Boos CJ, Lip GY, Blann AD. Circulating Endothelial Cells in Cardiovascular Disease J Am Coll Cardiol. 2006 Oct 17;48(8):1538-47.



"Type 2 Diabetes and Cardiovascular Disease: The Neel Hypothesis Revisited"

Prof. Peter J. Grant (biography)
English - 2006-05-07 - 49 minutes
(47 slides)

Summary :
In this presentation Prof. Grant talks about the Common Soil and Thrifty Genotype hypotheses and how they can be interpreted in light of new information that became available since their conception.

According to the Common Soil Hypothesis put forth by Stern in the 1980s, diabetes and cardiovascular disease are the same condition, underpinned by common genetic and environmental...

Learning objectives :
After viewing this presentation the participant will be able to discuss:

- The primary function of inflammation and thrombosis;
- The physiological nature of the adipocyte response to fat loading;
- The inflammatory atherothrombotic insulin resistance syndrome underpinning diabetes and cardiovascular disease;
- The relationship of abnormal cyclical responses to diabetes and cardiovascular disease.

Bibliographic references :
Reaven, GM. Banting Lecture 1988. Role of Insulin Resistance in Human Disease Diabetes. 1988; 37(12): 1595-1607

Norhammar, A., Tenerz, A., Nilsson, G., Hamsten, A., Efendic, S., Ryden, L., Malmberg, K. Glucose Metabolism in Patients with Acute Myocardial Infarction and no Previous Diagnosis of Diabetes Mellitus: A Prospective Study The Lancet. June 2002; 359(9324): 2140-2144

Moreno, PR., Murcia, AM., Palacios, IF., Leon, MN., Bernardi, VH., Fuster, V., Fallon, JT. Coronary Composition and Macrophage Infiltration in Atherectomy Specimens From Patients With Diabetes Mellitus Circulation. 2000; 102: 2180

Vinik, AI., Erbas, T., Park, TS., Nolan, R., Pittenger, GL. Platelet Dysfunction in Type 2 Diabetes Diabetes Care. 2001; (24): 1476-1485

Freeman, MS., Mansfield, MW., Barrett, JH., Grant, PJ. Genetic Contribution to Circulating Levels of Hemostatic Factors in Healthy Families With Effects of Known Genetic Polymorphisms on Heritability Arteriosclerosis, Thrombosis, and Vascular Biology. 2002; 22: 506

Dunn, EJ., Ariens, RAS., Grant, PJ. The Influence of Type 2 Diabetes on Fibrin Structure and Function Diabetologia. 2005; 48(6): 1198-1206

Dunlap, JC. Molecular Bases for Circadian Clocks Cell. January 1999; 96(2): 271-290

Ando, H., Yanagihara, H., Hayashi, Y., Obi, Y., Tsuruoka, S., Takamura, T., Kaneko, S., Fujimura, A. Rhythmic Messenger Ribonucleic Acid Expression of Clock Genes and Adipocytokines in Mouse Visceral Adipose Tissue Endocrinology. 2005; 146(12): 5631-5636

Montagnani, M., Golovchenko, I., Kim, I., Koh, GY., Goalstone, ML., Mundhekar, AN., Johansen, M., Kucik, DF., Quon, MJ., Draznin, B. Inhibition of Phosphatidylinositol 3-Kinase Enhances Mitogenic Actions of Insulin in Endothelial Cells J. Biol. Chem. January 2002; 277(3): 1794-1799

Turek, FW., Joshu, C., Kohsaka, A., Lin, E., Ivanova, G., McDearmon, E., Laposky, A., Losee-Olson, S., Easton, A., Jensen, DR., Eckel, RH., Takahashi, JS., Bass, J. Obesity and Metabolic Syndrome in Circadian Clock Mutant Mice Science. May 2005; 308(5724): 1043-1045



"Diabetes Mellitus: A Prothrombotic State"

Dr. Richard W. Nesto (biography)
English - 2005-05-11 - 38 minutes
(33 slides)

Summary :
In this presentation Dr. Nesto talks about the mechanisms in diabetes that are responsible for the increased tendency to clot formation.

The higher risk of acute myocardial infarction in diabetes is hypothesized to be due to more extensive and progressive coronary artery disease, the proinflammatory and prothrombotic state of coronary plaques, as well as diabetes-specific...

Learning objectives :
After viewing this presentation the participant will be able to discuss:

- Diabetes-associated changes in coronary plaques and blood contributing to thrombosis risk
- Effects of different anti-platelet therapies in diabetes

Bibliographic references :
1. Pedro R. Moreno, MD and Valentin Fuster, MD, PhD. New aspects in the pathogenesis of diabetic atherothrombosis J Am Coll Cardiol. 2004 Dec 21;44(12):2293-300.

2. Frank D. Kolodgie, Ph.D., Herman K. Gold, M.D., Allen P. Burke, M.D., David R. Fowler, M.D., Howard S. Kruth, M.D., Deena K. Weber, M.S., Andrew Farb, M.D., L.J. Guerrero, B.S., Motoya Hayase, M.D., Robert Kutys, M.S., Jagat Narula, M.D., Ph.D., Aloke V. Finn, M.D., and Renu Virmani, M.D. Intraplaque Hemorrhage and Progression of Coronary Atheroma. N Engl J Med. 2003 Dec 11;349(24):2316-25.

3. Antonia Sambola, MD; Julio Osende, MD; James Hathcock, PhD; Michael Degen, BSc; Yale Nemerson, MD; Valentin Fuster, MD, PhD; Jill Crandall, MD; Juan Jose Badimon, PhD. Role of Risk Factors in the Modulation of Tissue Factor Activity and Blood Thrombogenicity. Circulation. 2003;107:973.

4. Nerea Varo, PhD; David Vicent, MD, PhD; Peter Libby, MD; Rebecca Nuzzo, BSc; Alfonso L. Calle-Pascual, MD, PhD; María Rosa Bernal, PhD; Arturo Fernández-Cruz, MD, PhD; Aristidis Veves, MD, DSc; Petr Jarolim, MD, PhD; Jose Javier Varo, MD, PhD; Allison Goldfine, MD; Edward Horton, MD; Uwe Schönbeck, PhD. Elevated Plasma Levels of the Atherogenic Mediator Soluble CD40 Ligand in Diabetic Patients: A Novel Target of Thiazolidinediones. Circulation. 2003;107:2664.

5. Burton E. Sobel, MD; Janet Woodcock-Mitchell, PhD; David J. Schneider, MD; Robert E. Holt, BA; Kousuke Marutsuka, MD; ; Herman Gold, MD. Increased Plasminogen Activator Inhibitor Type 1 in Coronary Artery Atherectomy Specimens From Type 2 Diabetic Compared With Nondiabetic Patients: A Potential Factor Predisposing to Thrombosis and Its Persistence. Circulation. 1998;97:2213-2221.

6. John A. Colwell, MD, PHD and Richard W. Nesto, MD. The Platelet in Diabetes: Focus on prevention of ischemic events. Diabetes Care 26:2181-2188, 2003.



"Adiponectin - Novel 'Adipokine' with Metabolic and Vascular Effects"

Dr. Barry Goldstein (biography)
English - 2005-04-27 - 54 minutes
(44 slides)

Summary :
A number of factors or adipocytokines are secreted from adipose tissue, many of which affect insulin sensitivity and vascular endothelial function. Central abdominal fat in particular has been found to be associated with insulin resistance (1), and ectopic fat deposition in liver and muscle also causes insulin resistance in those tissues. PPARγ agonists such as the thiazolidinediones, which...

Learning objectives :
Key discussion points:

- How does increased visceral adiposity lead to insulin resistance and vascular dysfunction?
- What is adiponectin and why is it apparently so important?
- What is the significance of these findings for the action of TZDs?

Bibliographic references :
1. Carey DG, Jenkins AB, Campbell LV, Freund J, Chisholm DJ.Abdominal fat and insulin resistance in normal and overweight women: Direct measurements reveal a strong relationship in subjects at both low and high risk of NIDDM.Diabetes. 1996 May;45(5):633-8.

2. Michio Shimabukuro, Namio Higa, Tomohiro Asahi, Yoshito Oshiro, Nobuyuki Takasu, Tatsuya Tagawa, Shinichiro Ueda, Iichiro Shimomura, Tohru Funahashi and Yuji Matsuzawa Hypoadiponectinemia Is Closely Linked to Endothelial Dysfunction in Man J Clin Endocrinol Metab. 2003 Jul;88(7):3236-40.

3. Barry J. Goldstein and Rosario Scalia Adiponectin: A Novel Adipokine Linking Adipocytes and Vascular Function J Clin Endocrinol Metab. 2004 Jun;89(6):2563-8.


  Username :
  Password :
  Lost your password?

  Search our website
  Would you like to know more about insulin resistance? Are you looking for information pertaining to Type 2 Diabetes? You can find what you are looking for in over 2000 references available on CMEonDiabetes.


Copyright © 2002-2015 MULTILEARNING Group INC.. All rights reserved.  Disclaimer
Powered by Multiwebcast - webcast services